Journal
PHYSIOLOGY
Volume 29, Issue 2, Pages 108-121Publisher
AMER PHYSIOLOGICAL SOC
DOI: 10.1152/physiol.00009.2013
Keywords
-
Categories
Ask authors/readers for more resources
DPP4 inhibitors and GLP-1 receptor agonists used in incretin-based strategies treat Type 2 diabetes with different modes of action. The pharmacological blood GLP-1R agonist concentration targets pancreatic and some extra-pancreatic GLP-1R, whereas DPP4i favors the physiological activation of the gut-brain-periphery axis that could allow clinicians to adapt the management of Type 2 diabetes, according to the patient's pathophysiological characteristics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
